Oncology

 

The Peptide Receptor Radio-Isotope Therapy for Neuroendocrine Tumors (NET-PRRT) is currently the fastest growing and most successful example of a radio-isotope based personalized therapy.
Read more...
 
Radiology / Cardiology

 

The fully CE certified ITM Rhenium-PTA/PTCA™ is routinely provided to patients with progressed peripheral and cardiac endovascular disease (restenosis and in-stent restenosis).
Read more...
 
Onco-Dermatology

 

The ITM Rhenium-SCT™ is the new generation of non-invasive skin cancer therapy, provided by ITM OncoBeta GmbH - predominantly to patients with large and difficult to treat skin tumours .
Read more...
 
Radioisotopes

 

The portfolio of ITG radioisotopes and generators utilized in the ITM Group has been carefully selected and developed to comply with a set of narrow and challenging specifications.

The ITM radioisotope production and supply systems are optimized to meet the quality and supply standards (interuption free, security of supply) required in a dynamically developing environment of a new generation of targeted, personalized therapies.
Read more...
 

News

ITG has received the Manufacturing License for Lu-177 n.c.a.

As of December 2011, ITG Isotope Technologies Garching GmbH has successfully passed the audit of the GMP production of the...
Read more...

ITG Isotope Technologies Garching GmbH (Germany) announces broad collaboration with ANSTO (Australia) on radioisotopes

Garching, Germany, June 3, 2011. ITG Isotope Technologies Garching GmbH (ITG), a specialist in the development and production of innovative...
Read more...

Helmholtz Zentrum München and ITM AG enter antibody deal

Ascenion has mediated a license agreement between the Helmholtz Zentrum München and ITM Isotopen Technologien München AG providing the company...
Read more...